Organon: A High Cash Yield Hidden Behind Patent Fatigue [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Organon is an American pharmaceutical company spun off from Merck & Co. in 2021 with a focus on women's health, biosimilars, and established brands. Headquartered in Jersey City, it markets a portfolio that includes contraceptives such as Nexplanon, fertility treatments, and biosimilar therapeutics designed to provide cost-effective alternatives to branded biologics. Nearly a third of the company's revenue is derived from the United States, with the balance coming from global markets where it sells products in reproductive medicine, hormone therapies, and other therapeutic categories. Warning! GuruFocus has detected 7 Warning Signs with OGN. List of 52-Week Lows List of 3-Year Lows List of 5-Year Lows Is OGN fairly valued? Test your thesis with our free DCF calculator. In its most recent full-year results, Organon reported revenue of approximately $6.2 billion for 2025, a decline of about 3% from the prior year on both an as-reported and constant currency basis. Adjusted
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline [MSNBC.com]MSNBC.com
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)Business Wire
- New Public Listings for Canadians Living with Pulmonary Arterial Hypertension [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- 'My Dad Lost Everything': Jim Cramer 'Willing To Expose' His Father For Picking The Wrong Stock — And Missing Multimillionaire Opportunity [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (MRK) had its price target raised by Citigroup Inc. from $120.00 to $125.00. They now have a "neutral" rating on the stock.MarketBeat
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- MRK's page on the SEC website